GBI Research's analysis shows that the overall global musculoskeletal disorders therapeutics market for the five indications (which includes rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy) was valued at $33.4 billion in 2010, indicating a CAGR of 5.7% over the previous year. GBI Research forecasts the market to grow at a CAGR of 7.3% between 2010 and 2017, to record a sales value of $54.8 billion by 2017. The growth in major markets such as the US and the top five countries in the EU and Japan were driven by new developments that created more options in the treatment of rheumatoid arthritis, osteoporosis, osteoarthritis, muscular dystrophy and low back pain. The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). The future of the market is based on the success of the drugs in the pipeline; while the current musculoskeletal disorders market pipeline holds strong prospects for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the generic share continues to rise in the market.
Data and analysis on the musculoskeletal disorders therapeutics market in the leading geographies of the world - the US, the UK, Germany, France, Italy, Spain, and Japan.
Annualized market data for the market from 2002 to 2010, with forecasts to 2017 for the three indications - rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy.
Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
Share of the generics in the global musculoskeletal disorders therapeutics market and for the market of each indication that is covered in the report.
Key drivers and restraints that have had a significant impact on the market.
The competitive landscape of the market, including top companies benchmarking. The key companies studied in this report are Pfizer Inc., Eli Lilly, Johnson & Johnson, Amgen Inc. and Abbott Laboratories.
Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the musculoskeletal disorders therapeutics market.
Reasons to buy
Align your product portfolio to the markets with high growth potential.
Build effective strategies to launch their pipeline products by identifying potential geographies.
Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
Develop key strategic initiatives by studying the key strategies of top competitors.
Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.
GBI Research, the leading business intelligence provider, has released its latest report, “Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014”. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of the major musculoskeletal disorders, including rheumatoid arthritis, osteoporosis, osteoarthritis, low back pain and muscular dystrophy. The report also provides the share of generics in the global musculoskeletal disorders as well as in each indication market. It also provides the treatment flow algorithm for each of the five indications. The report examines the global musculoskeletal disorders treatment usage patterns. In addition, our research details the geographical distribution of musculoskeletal disorders markets across the US, the top five countries of Europe, and Japan.The report also includes insight into the musculoskeletal disorders R&D product pipeline and explores the competitive landscape, including major players in the musculoskeletal disorders therapeutics market. Finally, the report includes analysis of Mergers and Acquisitions (M&As) and licensing agreements that took place in the musculoskeletal disorders therapeutics market in recent years.
Global Musculoskeletal Disorders Therapeutics Market to Witnesses Moderate Growth as Generic Share Continues to Rise
In 2010, the global musculoskeletal disorders market was approximately $33.4 billion, representing a compound annual growth rate (CAGR) of 5.7% between 2002 and 2010. By 2017, the global market is estimated to reach $54.8 billion, indicating a CAGR of 7.3% between 2010 and 2017. The major reason behind the growth rate is the approval of Prolia (denosumab) during 2010. Although the market for management is highly competitive, blockbuster sales of Cymbalta (duloxetine HCl) coupled with improved diagnosis is expected to drive the market in the future.
The global musculoskeletal disorders market is expected to witness a series of patent expiries between 2010 and 2017, which includes some top selling drugs such as Cymbalta (duloxetine HCl) and Celebrex (celecoxib). While the current market pipeline has a prospect for growth in the future, these factors will not be able to completely offset the challenge from generic competition. Muscular dystrophy is one of the most commonly recognized musculoskeletal disorders, but there are no approved therapeutic options available for this disease. For this reason, the market's generic share continues to rise.
The Musculoskeletal Disorders Therapeutics Market is Concentrated with the Top Three Companies contributing approximately 45% of the Market Share
The global musculoskeletal disorders therapeutics market is dominated by three major pharmaceutical companies that account for approximately 43% of the total share of this market. The major market share is occupied by Abbott, followed by Johnson & Johnson and Amgen. The presence of various large as well as small pharmaceutical companies makes this market strong in terms of competition. However, the presence of blockbuster drugs has made these three companies the dominant players in this market. Abbott with Humira, the drug for rheumatoid arthritis, stands first with total revenues of $6.5 billion. Remicade, the drug used to treat rheumatoid arthritis, has made Johnson & Johnson the second largest player in the market with total revenues of $4.6 billion. Amgen, with rheumatoid arthritis drug, Enbrel occupies the third position in terms of market share with total revenues of $3.5 billion for the musculoskeletal disorder therapeutics market. This shows that the market is highly concentrated, leaving only 55% of the market open for other players to operate.
Unmet Need for Better Management of Musculoskeletal Diseases and Potential for Future Growth is Driving Companies to Invest in Research and Development
The research and development (R&D) pipeline for musculoskeletal disorders diseases is moderately healthy due to the presence of about 468 programs. These programs study drug candidates for the treatment of musculoskeletal disorders associated with osteoarthritis, osteoporosis, rheumatoid arthritis, low back pain and muscular dystrophy. However, the products in the pipeline do not look especially promising and may not provide better efficacy or safety levels compared to the drugs currently in the market. The pipeline consists of both first-in-class and 'me-too' products. The success of the first-in-class products will determine the future prospects for the industry. The high R&D activity indicates that the musculoskeletal disorders market has good potential for growth.
The musculoskeletal disorders market is marked by the extensive availability of generic drugs. The market will be considerably impacted by the patent expiries of several major drugs such as Cymbalta, Humira and Cerebrex. Another trend shaping the musculoskeletal disorders market worldwide is considerable M&A activity and licensing agreements among drug delivery firms; leading pharmaceutical companies are expected to develop tamper and abuse-resistant novel drug innovations in the forecast period.
Table of Contents
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Musculoskeletal Disorders Therapeutics Market to 2017 -Introduction
2.1 GBI Research Report Guidance
3. Musculoskeletal Disorders Therapeutics Market to 2017 - Market Overview
3.1.2 Annual Cost of Treatment
3.1.3 Treatment Usage Pattern
4. Musculoskeletal Disorders Therapeutics Market to 2017 -Geographical Landscape
4.1 Revenue Analysis by Geography
4.2 The US
4.2.2 Annual Cost of Treatment
4.2.3 Treatment Usage Patterns
4.3 Top Five Countries of Europe
4.3.2 Annual Cost of Treatment
4.3.3 Treatment Usage Patterns
4.4.2 Annual Cost of Treatment
4.4.3 Treatment Usage Patterns
5. Musculoskeletal Disorders Therapeutics Market to 2017 - Therapeutic Landscape
5.1 Rheumatoid Arthritis Therapeutics Market
5.1.3 Annual Cost of Treatment
5.1.4 Treatment Usage Pattern
5.1.5 Treatment Flow Algorithm
5.1.6 Drivers and Barriers for the Rheumatoid Arthritis Therapeutics Market
5.2 Osteoporosis Therapeutics
5.2.3 Annual Cost of Treatment
5.2.4 Treatment Usage Patterns
5.2.5 Treatment Flow Algorithm
5.2.6 Drivers and Barriers for Osteoporosis Therapeutics Market
5.3 Osteoarthritis Therapeutics
5.3.3 Annual Cost of Treatment
5.3.4 Treatment Usage Patterns
5.3.5 Treatment Flow Algorithm
5.3.6 Drivers and Barriers for Osteoarthritis Therapeutics Market
5.4 Low Back Pain Therapeutics
5.4.3 Annual Cost of Treatment
5.4.4 Treatment Usage Patterns
5.4.5 Treatment Flow Algorithm
5.4.6 Drivers and Barriers for Low Back Pain Therapeutics Market
5.5 Muscular Dystrophy Therapeutics
5.5.3 Annual Cost of Treatment
5.5.4 Treatment Usage Patterns
5.5.5 Treatment Flow Algorithm
5.5.6 Drivers and Barriers for Muscular Dystrophy Therapeutics Market
6. Musculoskeletal Disorders Therapeutics Market to 2017 - Pipeline Analysis
6.2 Musculoskeletal Disorders Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
6.2.1 NDA Filed Molecules
6.2.2 Phase III
6.2.3 Phase II
6.2.4 Phase I
6.2.5 Preclinical Phase
6.2.6 Discovery Phase
6.3 Profiles of Promising Molecules in the Musculoskeletal Disorders Therapeutics Market
6.3.1 YM529 (minodronate)
6.3.2 EX101 (alendronate)
6.3.3 MAbThera (rituximab)
6.3.4 Actemra (tocilizumab)
7. Musculoskeletal Disorders Therapeutics Market to 2017 - Competitive Profiling
7.1 Competitive Profiling
7.1.1 Abbott Laboratories
7.1.2 Johnson & Johnson
7.1.3 Amgen Inc.
7.1.4 Pfizer Inc
7.1.5 Eli Lilly and Company
8. Musculoskeletal Disorders Therapeutics Market to 2017 - Strategic Consolidations
8.1 Mergers and Acquisitions
8.1.1 Segmentation by Deal Value
8.1.2 Segmentation by Geography
8.2 Co-development Deals
8.2.1 Summary of Co-development Deals
8.3 Licensing Deals
8.3.1 Summary of Licensing Deals
9. Musculoskeletal Disorders Therapeutics Market to 2017 - Appendix